Watch RNAZ. Know when insiders buy.
One email the day a filing lands. Free.
RNAZ
Transcode Therapeutics, Inc.
1.69
+0.04 +2.42%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $28.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$42.8MNET CASH —52W 1.60 – 15.23SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.8M | −$6.8M | — | -7.17 | −$5.4M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$17.8M | −$17.8M | — | -21.28 | −$5M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$16M | −$13.4M | — | -18.10 | −$8.1M | — | — | Apr 15 |
| Q3 2025 · Sep 30 | — | — | — | −$4.6M | −$4.9M | — | -5.82 | −$4.1M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$4.2M | −$4.3M | — | -5.13 | −$4.2M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$3.2M | −$12.1M | — | -70.16 | −$3.1M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$5.1M | −$5.9M | — | -218.74 | −$3.1M | $500 | −$3.1M | Apr 15 |
| Q3 2024 · Sep 30 | — | — | — | −$2.2M | −$2.3M | — | -146.06 | −$3.9M | $13K | −$3.9M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$5.1M | −$5.2M | — | -680.23 | −$2.3M | $5K | −$2.3M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3.3M | −$3.3M | — | -21.35 | −$3.9M | $4K | −$3.9M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.1M | −$4.1M | — | -3145.35 | −$5.7M | $0 | −$5.7M | Apr 15 |
| Q3 2023 · Sep 30 | — | — | — | −$5.3M | −$5.3M | — | -48.44 | −$3.5M | $5K | −$3.5M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$28M | −$34.7M | — | -52.59 | −$19.5M | $7K | −$19.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$15.7M | −$16.8M | — | -1336.63 | −$13.3M | $22K | −$13.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$19.4M | −$18.5M | — | -3419.01 | −$18.1M | $36K | −$18.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$18.6M | −$17.6M | — | -1082.79 | −$15.8M | $101K | −$15.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$6.2M | −$6.8M | — | -0.81 | −$5.3M | $255K | −$5.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$727K | −$2.3M | — | -0.51 | −$493K | — | — | — | — |
Every number comes from Transcode Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.